This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
2018 Virtual Symposium: Management of T2DM Patients with Diabetic Kidney Disease: Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Disease Progression

2018 Virtual Symposium: Management of T2DM Patients with Diabetic Kidney Disease: Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Disease Progression

Format

Webcast

Time to Complete

1 hour

Released

December 24, 2018

Expires

December 24, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditsTM
1.00 / CNE Contact Hours (0.90 pharmacotherapy hour)
1.00 / CE for Pharmacists (0.10 CEUs)
1.00 / CPEU for Registered Dietitians

Accredited Provider

This activity is jointly provided by The University of Cincinnati and Tarsus Cardio Inc. dba Cardiometabolic Health Congress for ACCME credit. This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress for ANCC, CDR and ACPE credit.

Commercial Supporter

This activity is supported by educational grants from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC. and by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Program Description

Kidney disease has been recognized as a complication of type 2 diabetes mellitus (T2DM) since the 1950s, developing in approximately 35% of patients with T2DM and affecting as many as 50% of patients with diabetes through a 20 years’ duration. The prevalence of diabetic kidney disease (DKD) in the United States increased from 1988 to 2008 in proportion to the prevalence of diabetes. Among adults with diabetes, the prevalence of DKD has remained stable despite increased use of antihyperglycemic agents and renin-angiotensin-aldosterone system (RAAS) inhibitors.

Newer glucose-lowering agents appear to have glucose-independent effects on diabetic nephropathy and its progression. Recently published data from clinical trials assessing cardiovascular outcomes of SGLT2 inhibitors and GLP-1 receptor agonists (RAs) show positive affects on the development and progression of DKD.

This virtual symposium will utilize interactive infographics to provide an overview of the renal effects of antiglycemic agents, particularly GLP-1 RAs and SGLT2 inhibitors. Experts will identify patients who are at the greatest risk for DKD, discuss the underlying physiology of DKD, provide an overview of the mechanisms of action of SGLT2 inhibitors and GLP-1 RAs in relation to renal physiology, and how to effectively manage patients with T2DM and DKD based on the benefits and risks of SGLT2 inhibitors and GLP-1 RAs.

Intended Audience

The educational design of this activity addresses the needs of US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Describe the relationship between T2DM, hypertension, and cardiorenal syndrome
  • Review the most current T2DM algorithms and guidelines for the individualized treatment of complex patients, specifically those with DKD
  • Summarize the mode of action and effects of GLP-1 RAs and SGLT-2 inhibitors on renal physiology in patients with T2DM and DKD
  • Develop management plans for T2DM patients that consider the recently discovered renal effects of SGLT2 inhibitors and GLP-1 RAs

Conflict Of Interest Disclosure Policy

The University of Cincinnati requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the University of Cincinnati for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty

Matthew R. Weir, MD (Chair)
Professor and Director
Division of Nephrology
University of Maryland School of Medicine
Baltimore, MD

Dr. Weir discloses the following:
Consultant/Independent Contractor: MSD, Sanofi, Janssen, Akebia, BI, AstraZeneca, Relypsa, Boston Scientific

Robert D. Toto, MD
Professor of Medicine
Associate Dean for Clinical and Translational Research
University of Texas Southwestern Medical Center Dallas
Dallas, TX

Dr. Toto discloses the following:
Consultant/Independent Contractor: Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, Quest, Reata, Relypsa, ZS Pharma

Lance Sloan, MD, FACE, FASN
Clinical Assistant Professor - UTMB Galveston, TX
Medical Director of The Texas Institute for Kidney and Endocrine Disorders - Lufkin, TX
Medical Director of HC Polk Education Center - Lufkin, TX
Medical Director of SNG Dialysis - Lufkin, TX

Dr. Sloan discloses the following:
Consultant/Independent Contractor: AstraZeneca, Janssen, Merck, Pfizer
Speaker’s Bureau: Janssen, AstraZeneca, Boehringer Ingelheim, Lilly, Novo Nordisk

Accredited Provider Disclosure

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN, has nothing to disclose.
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Amanda Turner has nothing to disclose.
Erin Franceschini, MS, has nothing to disclose.
Karin McAdams has nothing to disclose.
Bruce Gebhardt, MD, has nothing to disclose.
Susan P. Tyler, M.Ed., CMP, CHCP, FACEHP, has nothing to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CMHC.

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The University of Cincinnati designates this online activity for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CNE Contact Hour(s)

Accreditation Statement

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

This educational activity for 1.00 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity. This activity includes 0.90 pharmacotherapy hours.

Credit

1.00

Type

CE for Pharmacists

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

Global Education Group designates this continuing education activity for 1.00 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge based activity. Universal Activity Number (UAN): 0530-9999-18-426-H01-P

Credit

1.00

Type

CPEU Credit

Accreditation Statement

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).

Designation Statement

CDR Credentialed Practitioners will receive 1.00 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of Cincinnati and CMHC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed all 4 modules, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any other questions relating to your certificate or other issues with the activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue